Latest Conference Articles

At SLEEP 2025, Fung discussed how combining a masked taper, CBT-I, and a nightly dose-tracking diary helped older adults achieve long-term benzodiazepine discontinuation.

At SLEEP 2025, Fung shared that masked taper plus CBT-I led to higher benzodiazepine discontinuation and improved sleep in older adults.

In this RAD 2025 interview, Paller highlights her team’s findings on disease and family burden of topic dermatitis in children.

Gulati covers the promises and pitfalls of the healthcare world’s increasing focus on obesity as a disease and the variety of complications to which it gives rise.

In this interview, Yosipovitch touches on the topics featured in his RAD 2025 presentation ‘Managing Itch,’ specifically regarding patients with atopic dermatitis.

At SLEEP 2025, Danny Eckert, PhD, discussed new drug therapies for OSA, including tirzepatide, AD109, potassium channel blockers, and acetazolamide.

Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.

HCPLive spoke with Bowles at SLEEP 2025 on the staggered schedule, referred to as 1/3/2/3, and how it impacts firefighters' sleep.

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives.

At SLEEP 2025, Colvonen discussed RCT findings that showed VeNS significantly improved PTSD and insomnia symptoms, offering a scalable solution for patients awaiting 1-on-1 care.

This interview with Peter Lio, MD, at RAD 2025 provides several insights into the topic of topical steroid withdrawal versus atopic dermatitis and what the distinction may be.

Martin reviews recent trends in cardiovascular disease and contributing underlying risk factors, describing them as a “call to action” for cardiovascular care.

In this interview at RAD 2025, Peter Lio, MD, highlighted whether precision medicine is a possibility in the near future in the atopic dermatitis management space.

In this Q&A discussion, Glick highlights several important points about topical steroid withdrawal and atopic dermatitis.

A recent meta-analysis reveals GLP-1 RAs significantly reduce adverse kidney outcomes, highlighting their potential in chronic kidney disease management.

Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

This study highlights rates among females with up to 6 years of upadacitinib use of major adverse cardiovascular events, VTE, and malignancy.

A recent study reveals how personality traits like neuroticism and extraversion influence bedtime procrastination in young adults, impacting sleep health.

Zulueta discussed Mount Sinai's incidental lung nodule program using AI tools to improve follow-up and recent findings from the program presented at ATS.

This Q&A interview features Jeff Yu, MD, in a discussion regarding his presentation on chronic hand eczema at the 2025 RAD Conference.

Incretin-based therapies for obesity and diabetes may be capable of treating a much wider range of diseases, including Alzheimer’s and Parkinson’s.

These late-breaking data highlight the real-world efficacy of upadacitinib for patients with atopic dermatitis who are either bio-naïve or bio-experienced.

Califf discusses the difficulty patients face in accessing healthcare information despite rapid technology and treatment advancements.

Patients with SCAD and comorbid depression had greater rates of heart failure, cerebrovascular disease, acute kidney injury, and atrial fibrillation.

This interview at RAD 2025 highlights several notes on dose flexibility in atopic dermatitis, with commentary by presenter Raj Chovatiya, MD, PhD.

Lopez reviews findings from an analysis of ARISE-HF highlighting racial and ethnic differences in baseline characteristics and diabetic cardiomyopathy disease progression.

The pooled analysis of BROOKLYN and BROADWAY data outline obicetrapib’s impact on HbA1c reduction and a trend toward lower new-onset diabetes risk.